SenzaGen AB
SenzaGen AB is a biotechnology company focused on developing and commercializing products for the detection of genotoxic impurities in pharmaceuticals, primarily through its HPLC-based test kits and services.
Business. SenzaGen AB (SENZA.ST) is a biotechnology and medical research company headquartered in Sweden. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. SenzaGen is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SenzaGen AB (SENZA.ST) is a biotechnology and medical research company headquartered in Sweden. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. SenzaGen is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
SenzaGen operates with a relatively strong liquidity position, as evidenced by a current ratio of 2.26 and cash and equivalents of 26.78 million SEK. However, the company reported negative operating and free cash flows of -6.82 million SEK and -7.67 million SEK, respectively, indicating ongoing cash burn. The debt-to-equity ratio of 0.24 suggests a conservative capital structure with limited leverage.
Profitability metrics are weak, with a return on equity of -14.91% and a return on assets of -9.98%, both significantly below the industry median for biotechnology firms. The company reported a net loss of 11.59 million SEK and an operating loss of 11.63 million SEK, reflecting the high R&D and operational costs typical of early-stage biotech firms.
The company's revenue is concentrated in a single business segment focused on genotoxic impurity testing, with no disclosed geographic diversification. This concentration increases exposure to market-specific risks, particularly in the pharmaceutical testing and regulatory compliance sectors.
Outlook for the current fiscal year is cautious, with no significant revenue growth expected. The company's capital expenditure of -3.01 million SEK reflects ongoing investment in R&D and infrastructure, but without clear revenue synergies in the near term. Analysts have set a uniform price target of 13.00 SEK, suggesting limited upside potential in the near term.
Risk factors include the company's reliance on a narrow product portfolio and the high costs of regulatory compliance in the pharmaceutical industry. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses suggest potential dilution pressure in the medium term.
Recent filings and transcripts indicate a focus on expanding the company's product portfolio and securing regulatory approvals for new test kits. No major strategic shifts or capital-raising events were disclosed in the latest filings.
- SenzaGen maintains a conservative capital structure with a low debt-to-equity ratio of 0.24 and strong liquidity.
- The company is unprofitable, with a return on equity of -14.91% and a net loss of 11.59 million SEK.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Analysts have set a uniform price target of 13.00 SEK, indicating limited near-term upside.
- The company's ongoing R&D investments and regulatory focus suggest a long-term growth strategy.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SenzaGen AB Market data — financials · 2026-05-29
- SenzaGen AB Market data — analyst estimates · 2026-05-29